RBC Capital raised the firm’s price target on Pennant Group (PNTG) to $38 from $26 and keeps an Outperform rating on the shares. The firm is updating its model following Pennant’s secondary offering and the partial closing of the Signature Healthcare acquisition while also rolling forward its valuation to 2025 estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group price target raised to $38 from $34 at Truist
- Pennant Group management to meet with Oppenheimer
- Levi Strauss mulls Dockers strategic alternatives: Morning Buzz
- Pennant Group 3.5M share Secondary priced at $31.00
- Pennant Group’s Stability in Question: CEO’s Stock Sale Plans Spark Investor Concerns